期刊
PATHOLOGY
卷 46, 期 4, 页码 274-282出版社
ELSEVIER
DOI: 10.1097/PAT.0000000000000110
关键词
outcome; microRNA; epigenetics; bladder cancer; Biomarkers; genomics; methylation
类别
资金
- Royal Australasian College of Surgeons
- Cancer Council Victoria
- Cybec Research Foundation
Molecular biomarkers are used routinely in the clinical management of several tumours such as prostate, colon, ovarian and pancreatic cancer but management decisions in bladder cancer remain dependent on clinical and pathological criteria, which are limited in their ability to predict outcomes. Molecular markers are urgently needed in detection, surveillance and prognostication of bladder cancer as well as to predict treatment response to intravesical and systemic therapies. Advances in cancer genomics and platforms for biomarker profiling have led to a plethora of biomarkers, which must now be rigorously validated in the clinical setting. Pre-clinical and clinical studies exploring the role of emerging targeted therapies to risk stratify and reduce cancer progression are also needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据